AU2001283925B2 - Valproic acid and derivatives thereof as histone deacetylase inhibitors - Google Patents

Valproic acid and derivatives thereof as histone deacetylase inhibitors Download PDF

Info

Publication number
AU2001283925B2
AU2001283925B2 AU2001283925A AU2001283925A AU2001283925B2 AU 2001283925 B2 AU2001283925 B2 AU 2001283925B2 AU 2001283925 A AU2001283925 A AU 2001283925A AU 2001283925 A AU2001283925 A AU 2001283925A AU 2001283925 B2 AU2001283925 B2 AU 2001283925B2
Authority
AU
Australia
Prior art keywords
cells
vpa
compound
histone deacetylase
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001283925A
Other languages
English (en)
Other versions
AU2001283925A1 (en
Inventor
Martin Gottlicher
Bernd Groner
Thorsten Heinzel
Peter Herrlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georg Speyer Haus
Original Assignee
Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg Speyer Haus filed Critical Georg Speyer Haus
Publication of AU2001283925A1 publication Critical patent/AU2001283925A1/en
Application granted granted Critical
Publication of AU2001283925B2 publication Critical patent/AU2001283925B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001283925A 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors Ceased AU2001283925B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00114088.8 2000-07-07
EP00114088A EP1170008A1 (en) 2000-07-07 2000-07-07 Valproic acid and derivatives thereof as histone deacetylase inhibitors
PCT/EP2001/007704 WO2002007722A2 (en) 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
AU2001283925A1 AU2001283925A1 (en) 2002-05-02
AU2001283925B2 true AU2001283925B2 (en) 2005-07-14

Family

ID=8169134

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001283925A Ceased AU2001283925B2 (en) 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors
AU8392501A Pending AU8392501A (en) 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8392501A Pending AU8392501A (en) 2000-07-07 2001-07-05 Valproic acid and derivatives thereof as histone deacetylase inhibitors

Country Status (10)

Country Link
US (2) US7265154B2 (enExample)
EP (2) EP1170008A1 (enExample)
JP (1) JP2004504347A (enExample)
AT (1) ATE295725T1 (enExample)
AU (2) AU2001283925B2 (enExample)
CA (1) CA2414967C (enExample)
DE (1) DE60110912T2 (enExample)
ES (1) ES2239677T3 (enExample)
PT (1) PT1301184E (enExample)
WO (1) WO2002007722A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
WO2003018767A2 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
EP1293205A1 (en) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (en) * 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
IL149404A0 (en) * 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
CA2508052A1 (en) * 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
KR100659779B1 (ko) 2004-09-04 2006-12-19 주식회사 바이넥스 히스톤 디아세틸라제 억제제를 함유하는 중간엽줄기세포의 골분화유도용 조성물 및 이를 이용한 골분화증가방법
US7642275B2 (en) * 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
EP2091525A1 (en) * 2006-12-06 2009-08-26 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
US8293513B2 (en) * 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
EP2236503B1 (en) 2009-04-03 2014-02-26 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (en) 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
US20120165384A1 (en) * 2009-09-07 2012-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Inhibition of histone acetyltransferases by ctk7a and methods thereof
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
WO2015168621A1 (en) * 2014-05-02 2015-11-05 Oncoethix Sa Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
CN105622712B (zh) * 2014-10-27 2019-08-27 天津金耀集团有限公司 一种甾体3-酮-4-烯物合成工艺
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20210386787A1 (en) * 2018-10-12 2021-12-16 Life Technologies Corporation Hematopoietic Stem and Progenitor Cell Expansion System
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
KR20240070504A (ko) * 2021-07-14 2024-05-21 샤흐 캐비아 리미티드 비포유동물 수생동물 세포 및 추출물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006821A1 (en) * 1994-08-30 1996-03-07 American Biogenetic Sciences, Inc. Neurotrophic and antiproliferative compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672746A (en) * 1994-08-30 1997-09-30 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
EP0855024A4 (en) * 1995-09-20 2001-08-22 Merck & Co Inc HISTONE DEACETYLASE AS THE ATTACK POINT FOR ANTIPROTOZOIC ACTIVE SUBSTANCES
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1997047307A1 (en) * 1996-06-14 1997-12-18 The Uab Research Foundation Use of histone deacetylase inhibitors to activate transgene expression
EP0961614A4 (en) * 1996-12-30 2002-07-24 Univ Bar Ilan OXYALKYLESTERS CONTAINING AND USING THE TRICARBOXYL ACIDS
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
WO1999023885A1 (en) * 1997-11-10 1999-05-20 The Salk Institute For Biological Studies Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP1170008A1 (en) 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006821A1 (en) * 1994-08-30 1996-03-07 American Biogenetic Sciences, Inc. Neurotrophic and antiproliferative compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Epilepsia (1992) vol 33 (no 4), pages 729-735 *
European Journal of Internal medicine (1994), vol 5 (no 4), pages 325-328 *
Folia Pharmacol Japonica (1978), vol 78 (no 8), pages 907-923 *
Strahlentherapie und Onkologie (2000), vol 176 (no 6), pages 251-258 *

Also Published As

Publication number Publication date
DE60110912D1 (de) 2005-06-23
JP2004504347A (ja) 2004-02-12
CA2414967A1 (en) 2002-01-31
US7265154B2 (en) 2007-09-04
EP1170008A1 (en) 2002-01-09
WO2002007722A3 (en) 2002-07-18
CA2414967C (en) 2009-08-25
ES2239677T3 (es) 2005-10-01
AU8392501A (en) 2002-02-05
EP1301184B1 (en) 2005-05-18
DE60110912T2 (de) 2005-10-20
US20040087652A1 (en) 2004-05-06
WO2002007722A2 (en) 2002-01-31
EP1301184A2 (en) 2003-04-16
PT1301184E (pt) 2005-07-29
US20070232696A1 (en) 2007-10-04
ATE295725T1 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
CA2414967C (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
AU2001283925A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
Nelson et al. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes
Rousseaux et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ
Ross et al. Retinoids in embryonal development
Clay et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells
EP0991636B1 (en) Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
Hall et al. Peroxisome Proliferator‐Activated Receptor β/δ in the Brain: Facts and Hypothesis
Nagpal et al. Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi’s sarcoma
Matsushima-Nishiwaki et al. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid
Polvani et al. Nuclear receptors and pathogenesis of pancreatic cancer
Liu et al. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARα/γ ligand TZD18
AU2002338716A1 (en) Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
US20100234402A1 (en) Methods and compositions for treating spinal muscular atrophy
JP2014076953A (ja) レチノイドｘ受容体パーシャルアゴニスト化合物及びこのレチノイドｘ受容体パーシャルアゴニスト化合物を有効成分として含有する薬剤
Gayarre et al. Differential selectivity of protein modification by the cyclopentenone prostaglandins PGA1 and 15-deoxy-Δ12, 14-PGJ2: role of glutathione
Sunami et al. Histone acetyltransferase p300/CREB-binding protein-associated factor (PCAF) is required for all-trans-retinoic acid-induced granulocytic differentiation in leukemia cells
Vourtsis et al. Effect of an all-trans-retinoic acid conjugate with spermine on viability of human prostate cancer and endothelial cells in vitro and angiogenesis in vivo
Silva et al. Cellular and molecular effects of silymarin on the transdifferentiation processes of LX-2 cells and its connection with lipid metabolism
Lucarelli et al. Troglitazione affects survival of human osteosarcoma cells
Wright et al. Functional activation of PPARγ in human upper aerodigestive cancer cell lines
Lee et al. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs
Hayashi et al. Effect of 9-cis-retinoic acid on oral squamous cell carcinoma cell lines
JP5885140B2 (ja) Ｒｘｒパーシャルアゴニスト
Zhu et al. PML-RARα stabilized by zinc in human acute promyelocytic leukemia NB4 cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired